Genmab A/S

365 articles with Genmab A/S

• 

  Genmab and Janssen Head to Arbitration Table Over Darzalex Royalties

  9/23/2020

  In a brief statement, Genmab said it initiated binding arbitration related to two matters under its Darzalex (daratumumab) license agreement with Janssen Biotech.

• Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

  9/21/2020

  Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 - Data Featured in Late-Breaking Proffered Paper Oral Presentation - - Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA - BOTHELL, Wash. & COPENHAGEN, Denmark--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) an

• AbbVie and Genmab Announce Broad Oncology Collaboration

  6/10/2020

  AbbVie and Genmab entered into a broad collaboration to jointly develop and commercialize three of Genmab's next-generation bispecific antibody products, including epcoritamab

• 

  AbbVie Plunks Down $750 Million Upfront for Cancer Therapy Deal with Genmab

  6/10/2020

  The collaboration will focus on the development of three of Genmab's bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.

• Tavotek Announces a Research Agreement with Genmab for the Development of Bispecific Antibodies using Genmab's DuoBody® Platform against a Pair of Disease Relevant Targets

  5/25/2020

  Tavotek Biotherapeutics, a biotech company which develops novel biologics for autoimmune diseases and oncology, announced that it has entered into a research agreement with Genmab A/S of Denmark to create and develop bispecific antibodies using Genmab's DuoBody® technology platform against disease relevant target antigens.

• 

  A Look at 5 Big and Interesting Biotech IPOs for 2019

  12/20/2019

  Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.

• Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

  12/19/2019

  Genmab A/S (Nasdaq: GMAB) and CureVac AG announced today that Genmab and CureVac have entered into a research collaboration and license agreement.

• Genmab Announces Financial Results for the First Nine Months of 2019

  11/6/2019

  Completion of public offering and listing of American Depository Shares (ADSs) on Nasdaq Global Select Market under the symbol “GMAB.” Total gross proceeds from the issuance of new shares amounted to USD 582 million (DKK 3,873 million) with a corresponding increase in share capital of 3,277,500 ordinary shares or 32,775,000 ADSs

• 

  Clinical Catch-Up: August 25-30

  9/3/2019

  Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
• 

  Novartis' Cancer Drug Arzerra Beats Out Sanofi's Aubagio in Treating Multiple Sclerosis

  8/30/2019

  The trials met the primary endpoints, with ofatumumab demonstrating a highly significant and clinically meaningful decrease in the number of confirmed relapses. The trials also hit key secondary endpoints, delaying the time to confirmed disability progression.
• 

  Genmab Raises $506 Million in IPO

  7/18/2019

  Genmab A/S, located in Copenhagen, Denmark, raised $506 million with its initial public offering (IPO). The company trades on the Nasdaq under the ticker symbol GMAB.

• Genedata Biopharma Platform Adopted by Genmab to Streamline Biotherapeutics R&D Operations

  7/9/2019

  Genedata E2E software solution to increase speed and efficiency of discovery and development of Genmab’s next-generation cancer therapies

• 

  Another Win For Darzalex as FDA Approves Combination Treatment For Multiple Myeloma

  6/28/2019

  Darzalex in combination with lenalidomide and dexamethasone was approved as a first-line treatment for multiple myeloma patients who are ineligible for autologous stem cell transplant.
• 

  Genmab and Janssen Team Up to Develop Next-Generation CD38 Antibody

  6/11/2019

  The agreement is the outcome of preclinical research on novel CD38 targeting concepts conducted by Genmab.
• 

  Already Public in Denmark, Genmab Files for $500 Million IPO in the U.S.

  5/29/2019

  The company’s board of directors hasn’t made a final decision to proceed with the listing.
• 

  FDA Approves J&J and GenMab’s Split-Dosing Regimen for Darzalex

  2/12/2019

  Darzalex (daratumumab) for intravenous infusion is approved in the U.S. in combination with bortezomib, melphalan and prednisone for patients with newly diagnosed multiple myeloma (MM) who are ineligible for autologous stem cell transplant.

• MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab

  1/31/2019

  MorphoSys AG announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute.

• Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab

  1/29/2019

  MorphoSys AG announces that it was informed that in its lawsuit against Janssen Biotech and Genmab A/S, the United States (U.S.) District Court of Delaware has ruled in a Court Order on January 25, 2019, that the asserted claims of three MorphoSys patents with U.S. Patent Numbers 8,263,746, 9,200,061 and 9,758,590 are invalid.

• 

  Upcoming Highlights from the 60th Annual American Society of Hematology Meeting

  11/30/2018

  The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
• 

  Genmab and Johnson & Johnson’s Darzalex Dazzles in Multiple Myeloma Trial

  10/30/2018

  Denmark-based Genmab A/S released topline data from its Phase III MAIA trial of a drug it licensed to Johnson & Johnson’s Janssen Biotech, Darzalex (daratumumab).